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Metabolic syndromeAquaglyceroporins are integral membrane proteins that are permeable to glycerol as well as water. The move-
ment of glycerol from a tissue/organ to the plasma and vice versa requires the presence of different aquaglycero-
porins that can regulate the entrance or the exit of glycerol across the plasma membrane. Actually, different
aquaglyceroporins have been discovered in the adipose tissue, small intestine, liver, kidney, heart, skeletal mus-
cle, endocrine pancreas and capillary endothelium, and their differential expression could be related to obesity
and the type 2 diabetes.
Here we describe the expression and function of different aquaglyceroporins in physiological condition and in
obesity and type 2 diabetes, suggesting they are potential therapeutic targets for metabolic disorders.
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Glycerol, chemically a polyol, is the backbone of triglycerides (TG)
and a precursor of phospholipids; it is an important intermediate in car-
bohydrate and lipid metabolism, and functions as a shuttle of electrons
from cytosol to mitochondria by regenerating NAD+ from NADH [1].AQP, aquaporin; GlpF, glycerol
ype; AMPK, AMP-activated pro-
NASH, steatohepatitis; VRAC,
dicine, HumanPhysiologyUnit,The digestion of dietary TG by pancreatic lipase produces mono- and
diacylglycerols,which are absorbedby the small intestinalmucosa. A less-
er amount of glycerol is also absorbed in the free form (see section 5,
“Small Intestine”) due to the low concentration of glycero-kinase (GK)
within the enterocyte. Monoglycerides and fatty acids undergo TG re-
synthesis. TG enter the bloodstreamas chylomicrons andVLDL. A lipopro-
tein lipase attached to the capillary endothelial cells of adipose tissue,
muscles and the heart hydrolyzes TG to free fatty acids and glycerol.
Fatty acids are actively transported into tissueswhereas glycerol ismainly
converted to glycerol-3-phosphate (glycolysis intermediate) by GK in the
liver and the kidney. Glycerol needs to be activated by a phosphorylation
reaction before entering the carbohydrate and lipid metabolism.
Glycerol plasma concentration is determined primarily by the
amount released by adipose tissue lipolysis, but also by the amount
Table 1
Aquaglyceroporins: main organ/tissue expression and localization, and their related functions.
Aquaporin Localization Main physiological functions
AQP3 Gastrointestinal tract⁎ Water and small solutes absorption and secretion
Kidney⁎ Contribute to urinary concentration
Adipose tissue⁎ Glycerol metabolism
Skin [139,140] Skin barrier, hydration and elasticity, cell proliferation and migration (tumorigenesis, wound healing)
Lymphocytes/Dendritic cells [141,142] Activation, proliferation, migration
Erythrocytes [143,144] Glycerol transport in human erythrocytes and ROS cleaning system by primitive erythroid cells
Female reproductive system [145] Vaginal lubrication, cervical water balance in pregnancy and parturition, water and non-charged solutes
in placenta
Male reproductive system [145] Maintenance of normal fertility
Eye [146] Corneal wound healing, involvement in the postnatal retina development
Heart/skeletal muscle⁎ Glycerol transport to be used for energy production
Respiratory tract [147] Water homeostasis in the epithelia of the upper and lower respiratory tract
Mammary gland [148,149] Production of the aqueous component of the milk
Articular cartilage [150] Chondrocyte volume regulation and extracellular matrix
Inner Ear [151,152,153] Water homeostasis of perilymph and endolymph
AQP7 Gastrointestinal tract⁎ Water and small solutes absorption and secretion
Kidney⁎ Involvement in glycerol reabsorption
Adipose tissue⁎ Glycerol metabolism
Heart/skeletal muscle⁎ Transport of glycerol to be used for energy production
Endocrine pancreas⁎ Could be involved in insulin production/secretion and in the reduction of β-cell mass
Female reproductive system [145,154] Endometrial decidualization; ﬂuid transport into antral follicles
Male reproductive system [145] Sperm maturation, storage and motility; seminiferous tubule ﬂuid production.
Eye [155] May participate in water transport into the vitreous body
Inner Ear [151,152,153] Water homeostasis of perilymph and endolymph
AQP9 Gastrointestinal tract [156] Involvement in the synthesis/secretion of a certain type of mucus
Liver⁎ Glycerol uptake for gluconeogenesis
Adipose tissue⁎ Glycerol metabolism
Inner ear [151,152,153] Water homeostasis of perilymph and endolymph, may be involved in the vestibular sensory transduction
system
Female reproductive system [145,157] Endometrial decidualization, epithelial water transport in the oviduct and the movement of the embryo
from the oviduct to the uterus, ﬂuid transport into antral follicles, transport of water and/or non-charged
solutes across the placenta
Male reproductive system [145] Water and small solutes transport in Leydig cells; epididymal and seminiferous tubules ﬂuid formation
Eye [146,155] may serve to transport lactate, glycerol and metabolites in the retina
Bone [158,159,160] Osteoclast differentiation and cell fusion process (in stressed condition?)
Erythrocytes [161] AQP9 is the major pathway for glycerol and other small uncharged solutes transport in mouse erythrocytes
Neutrophil leukocyte [162,163,164] Cell motility
Brain [165] Possible involvement in glucose energy metabolism in astrocyte and in some catecholaminergic neurons
Skin [80] Involved in maintaining skin hydration.
AQP10 Gastrointestinal tract⁎ Water and small solutes absorption and secretion
Adipose tissue⁎ Glycerol metabolism
Male reproductive system [166] Water balance maintenance
Skin [140] Involved in skin barrier
⁎ See related section for references.
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reabsorbed in the kidney tubules [2,3,4,5,6].
In the interprandial state, in starvation and in exercise, the glycerol
from lipolysis represents an important substrate for gluconeogenesis to-
gether with lactate, pyruvate and the amino acids alanine and glutamine
[7,8,9]. In prolonged starvation, the amount of glycerol metabolized to
glucose reached 76% in obese subjects [7]. Adipocyte lipolysis is a highly
regulated process: it is activated byβ-adrenergic agonists,melanocortins,
thyroid-stimulating hormone and atrial natriuretic peptide, leptin, gluco-
corticoids (both directly and through permissive action) and growth hor-
mone and it is inhibited by insulin, neuropeptide Y and peptide YY [10].
However, all themetabolic reactions described above can only occur
intracellularly, after the glycerol has crossed the plasmamembrane bar-
rier. Glycerol transport across cell membranes requires speciﬁc proteins
called aquaglyceroporins, a subfamily of the water channel proteins
aquaporins (AQPs), [11]. For these reasons AQP expression and func-
tioning play a key role be implicated in the control of fat accumulation
and in the associated metabolic alterations.
2. Aquaporins
Aquaporins are integral membrane proteins that were initially
thought to function only as bidirectional water-selective channels, but
they have successively been found to play a role in important cellularfunctions, such as cell proliferation, cell differentiation, cell migration
and cell adhesion [12,13,14]. Thirteen water channel proteins have
been identiﬁed in mammals and they have been divided into three
groups based on their structural and functional characteristics:
(i) aquaporins (AQP1, 2, 4, 6 and 8) selectively permeable to water;
(ii) aquaglyceroporins (AQP3, 7, 9 and 10) permeable to glycerol, urea
and other small solutes in addition to water (see Table 1 for tissue local-
ization and main physiological functions); (iii) S-aquaporins (AQP11
and 12), with peculiar intracellular localization and functions, currently
under study [12,15,16]. AQPs are small proteins (26–34 kDa) assembled
as homotetramers in the membrane, with each monomer containing a
single aqueous pore. As demonstrated for AQP1, themonomer sequence
consists of two repeated segments (tandem repeats), each formed by
three α-helical transmembrane domains and ﬁve loops (three external
and two internal to the membrane), with the amino-and carboxy-
termini intracellularly localized. The two tandem repeats contain (in
the second and the last loop) two highly conserved domains called
NPA boxes (Asn-Pro-Ala) that play a crucial role in pore formation. In
the “hourglass model”, the six transmembrane helices form the walls
of the channel, like two connected bulbs, while the two NPA motifs,
folding in the center of the membrane, represent the narrowest part
of the pore. This channel conformation allows a trickle of water mole-
cules in single-ﬁle from one side of the membrane to the other, which
depends exclusively on the presence of an osmotic gradient across the
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both electrostatic and steric factors. In particular, the speciﬁcity is deter-
mined by the constriction region; the target of mercury compounds,
which are known inhibitors of almost all AQPs (AQP4 being the most
studied exception) has been identiﬁed close to this region [17]. Point
mutation experiments demonstrated that the Cys189 of AQP1, located
in the narrowest site of the pore, is the residue that binds covalently
the sulfhydryl-reactive heavy metal ions [18,19,20].
Aquaglyceroporins sequencing revealed a common additional con-
served Asp residue near the second NPA box that enlarges the pore to
permit glycerol to permeate [12,21].
Moreover, the selectivity ﬁlter (the constriction region) in the center
of the pore is ensured by the diameter and composition of the aromatic
arginine region (ar/R) through electrostatic and steric factors that form
a barrier to protons and other cations. In the human AQP1 the pore di-
ameter is about 2.8 Å, with the ar/R constriction region formed by the
juxtaposition of hisidine/arginine residues. In human aquaglyceropo-
rins and in the glycerol facilitator (GlpF), the aquaglyceroporin
expressed in Escherichia coli, the presence of a smaller amino acid resi-
due in the constriction regionwith the glycine substituting the histidine
makes the pore larger (pore diameter of about 3.5 Å) and permeable
also to glycerol [22,23,24,25,26].
Although the selectivity of AQPs and aquaglyceroporins towater and
polyols like glycerol is well established, a potentiallywider permeability
also to gases and other small solutes has been suggested [27,28] and is
currently being discussed [29]. AQP8 shows remarkable permeability
to urea and ammonia, so that in the liver this AQP seems to be involved
in the detoxiﬁcation processes [27,30]. In addition, AQP8 and probably
almost all AQPs to different extents, are able to transport hydrogen per-
oxide; this implies AQPs may have a role in mediating oxidative stress
and in tuning intracellular signaling [24,31].
An interesting feature of aquaglyceroporins is their ability to facili-
tate arsenous acid and arsenite transmembrane transport, with AQP9
being themost efﬁcient channel, followed by AQP7 [32,33]. Themecha-
nism bywhich arsenic and other metalloids can permeate aquaglycero-
porins is that at physiological pH they mimic the characteristics of the
glycerol molecule: they are undissociated, similarly uncharged, and
their volume is only slightly smaller than that of glycerol [34]. The
presence of high levels of AQP9 protein in the liver could therefore
play a role in arsenic detoxiﬁcation by mediating metalloid inﬂow into
hepatocytes [35]. Interestingly, AQP9 expression in leukocytes [36] has
proved fundamental for the transport of arsenic trioxide, so that this
compound can be used as an antineoplastic chemotherapy drug; in
September 2000, the FDA approved arsenic reintroduction for the treat-
ment of relapsed or refractory acute promyelocytic leukemia [34,37,38].
Unlike other aquaporins, AQP6 shows a surprisingly low water per-
meability in basal conditions, but its water channel function can be
turned on by mercury treatment and by an acidic environment. More-
over, this activation of AQP6 water permeability is accompanied by a
marked anion permeability with the following permeability order:
NO3− N I−N N Br− N Cl− N N F− N N SO42− [39,40].
Finally, a permeability of AQPs to gases such as CO2 and nitric oxide,
and to a variety of non-charged solutes, like carbamides, purines and
pyrimidines has also been proposed [27,36,41], but needs further
validation.
Here we will consider the handling of glycerol by the adipose tissue,
the liver, the gastrointestinal tract, the kidney, the endocrine pancreas,
the heart/skeletal muscle and by microvessels.
3. Adipose tissue
AQP7was theﬁrst glycerol channel identiﬁed in the adipose tissue of
humans and rodents, and for ﬁfteen years it was considered the only
aquaglyceroporin in this tissue [42,43]. More recently, other aquaglyc-
eroporins have been found in human adipocytes: AQP3 and AQP9
[44], AQP10 [45] and AQP11 [46]. Interestingly, AQP10 protein isexpressed in humans, while in mice and in other animal species it is a
nonfunctional pseudogene [12,47,48].
As for cellular and subcellular expression and localization, research
yielded conﬂicting results. The ﬁrst attempts to deﬁneAQP7 localization
in adipocytes were performed in murine and human cell cultures,
followed by immunohistochemical studies in human adipose tissue.
The results supported an expression conﬁned to adipocytes [49,50,51]
with an intracellular localization of the protein, which migrated to the
plasma membrane in response to β-adrenergic stimuli [44,45,49,51].
Other studies found instead that AQP7 is expressed in the endothelial
cells of small vessels within the adipose tissue [52,53]. Laforenza et al.
found that AQP7 is localized in both adipocyte and endothelial plasma
membranes of human adipose tissue [45]. This double localization is
now conﬁrmed [54].
AQP3 and 9were found in thehuman subcutaneous and omental ad-
ipose tissue with an mRNA concentration similar to that of AQP7, with
the omental AQP3 even more expressed [44]. AQP3 and AQP7 are both
localized in the membranes surrounding the lipid droplets and in the
plasma membranes of adipocytes, while AQP9 is constitutively
expressed in the plasma membranes [44]. Since other studies both in
mice and in humans were unable to detect these AQPs [49,53,55], and
given the absence of appropriate antibody controls, these results need
to be conﬁrmed. AQP10 was found at mRNA and protein level in
human subcutaneous adipose tissue and localized both in the mem-
branes surrounding the lipid droplets and in the plasma membranes
[45]. Miranda et al., searching for more aquaglyceroporins in the adi-
pose tissue, did not ﬁnd traces of AQP10 transcript [51]. More recently,
AQP11 has been identiﬁed in both subcutaneous and human mature
visceral adipocyte cell models, localized in proximity of the lipid drop-
lets; both hAQP11 silencing and overexpression demonstrated its
water and glycerol permeability [46]. However, the intracellular locali-
zation of AQP11 and its unexpected glycerol permeability need to be
further conﬁrmed.
A study byKishida et al. [49] provided theﬁrst evidence for the funda-
mental role of AQP7 in the release of glycerol fromadipocytes. The results
showed that AQP7 functions as a glycerol channelwhich is regulatedneg-
atively by insulin, positively by fasting and which is more abundantly
expressed in obese mice with insulin resistance. Epinephrine, glucagon,
andACTHwere ineffective at regulating AQP7mRNAexpression. Howev-
er, epinephrine induced AQP7 translocation to the plasma membranes
from the intracellular regions. Kuriyama et al. conﬁrmed these ﬁndings
and demonstrated that insulin coordinates the regulation of adipose
AQP7 and liver AQP9 expression in fasting/refeeding [56]. Moreover,
obese insulin-resistant db+/db+mice showedhigher AQP7 and 9 levels
compared to controls. A similar increase in AQP7mRNAwas observed in
adipose tissue from Otsuka Long-Evans Tokushima Fatty rats, an animal
model of type 2 diabetes with obesity, compared to normal Long-Evans
Tokushima Otsuka rats [57].
In addition to insulin, other hormones have been demonstrated to
regulate aquaglyceroporin expression in the adipose tissue. Isoprotere-
nol, tumor necrosis factor α and dexamethasone reduced the expres-
sion of AQP7 mRNA of cultured 3 T3-L1 adipocytes by 62, 60 and 39%,
respectively, while angiotensin-2, growth hormone, and triiodothyro-
nine had no effect [58]. The effects of leptin and ghrelin, two hormones
involved in the regulation of food intake and bodyweight, were also an-
alyzed. Acylated and desacyl-ghrelin were found to decrease AQP7
mRNA expression and to stimulate lipid accumulation inhumanvisceral
adipocytes after incubation for 48 h [59], while 30 min incubation with
leptin increased AQP3 and decreased AQP7 and AQP9 protein in human
cultured omental adipocytes [44].
Studies in two independent AQP7-knockout (KO) mouse lines [55,
60,61] gave a boost to this topic. Initially, the ﬁrst AQP7-KO mouse
line did not show any change in either body weight or fat mass at
least until 10 weeks of age [55]. However, the mice had lower plasma
glycerol concentration, normal plasma FFA, and high glycerol content
in adipocytes after fasting; in these AQP7-KO mice, the increase in
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Similar results were obtained in AQP7-silenced 3 T3-L1 adipocytes.
AQP7-KO mice also showed a slower increase in plasma glycerol and
rapid reduction in plasma glucose during prolonged fasting. The same
Authors one year later observed that the body weight of AQP7-KO
mice signiﬁcantly increases after 12weeks of age andmice develop obe-
sity [61]. AQP7-KO mice showed adipocyte hypertrophy, increased GK
activity and susceptibility to obesity, and insulin resistance after being
fed a high-fat/high-sucrose diet. Results obtained independently using
a different AQP7-KO mice line evidenced a 3.7 fold increase in body fat
mass after 16 weeks of age [60]. Adipocytes were hypertrophic, had el-
evated contents of glycerol, free fatty acids and triglycerides, and had an
impaired glycerol uptake/release.
As a whole, AQP7 deﬁcientmice show amarked reduction in glycer-
ol release; the increased glycerol accumulation and the activation of GK
enhances triacylglycerol synthesis, which in turn results in adipocyte
hypertrophy and obesity. Moreover, glucose homeostasis was also im-
paired in AQP7-KO mice, which showed a tendency to develop
insulin-resistance [60,61].
To complicate the picture, these results were not conﬁrmed by sub-
sequent studies using different AQP7-KO mouse models with different
genetic backgrounds [52,62]. In particular, the AQP7-KO mouse model
did not show any obesity onset in adulthood. However, Skowronski
et al. found AQP7 expression in the adipose tissue capillaries but not
in adipocytes; they found an increased urine glycerol level in 24 h
starved AQP7 null mice and an upregulation of AQP7 in the adipose tis-
sue of streptozotocin diabetic mice and in WT mice after prolonged
fasting [52].
Surprisingly, Matsumura et al., using the most recent AQP7- KO
mouse model, found no change in adiposity, but showed an increased
islet glycerol concentration, increased GK and increased triglyceride
content in pancreatic islets. This suggests the existence of a common al-
teration in different tissues of different AQP7-KO mouse models [62].
Differently from what observed in rodents, in humans defective
AQP7 was not correlated with either obesity or type 2 diabetes. The
ﬁrst study looking for human AQP7 mutations found three missense
mutations (R12C, V59L and G264V), and two silent mutations (A103A
and G250G), with G264V being the only one that showed a loss of
both water and glycerol permeability. Surprisingly, the subject, homo-
zygous for the non-functional AQP7-G264V mutant, was neither obese
nor diabetic and displayed only a defective exercise-induced plasma
glycerol increase [63]. These ﬁndings were successively conﬁrmed
[64]. More recently, three unrelated childrenwith the AQP7 G264Vmu-
tation were also found to be neither obese nor diabetic, with normal
glycerolemia, but with hyperglyceroluria [65]. A mild platelet secretion
defect and psychomotor retardationwere also observed, but the associ-
ation of these impairments with the AQP7 mutation has not been
demonstrated.
The differences observed between AQP7 nullmice developing obesi-
ty and humans lacking a functional AQP7 without an obese/diabetic
phenotype have prompted the research community to look for other
glycerol pathways in the human adipose tissue. As mentioned above,
AQP3, 9 and 10were found in human adipocytes; their function in glyc-
erol transport and their regulation by lipogenic and lipolytic stimuli
have been demonstrated [44,45]. Immunolocalization and hormone
regulation experiments demonstrated that AQP3, AQP7 and AQP10 re-
side in both adipocyte plasma membranes and lipid droplets mem-
branes, that insulin stimulation enhances AQP3,7,10 labeling around
the lipid droplets and that isoproterenol induces AQPs translocation to
the plasma membrane [44,45]. As above indicated, AQP9 appears to be
constitutively present in the adipocyte plasma membranes [44].
Although not always consistently, AQP7 mRNA and protein expres-
sion in human adipose tissue have been shown to be altered in both
obesity and insulin resistance [44,64,66,67,68]. Kuriyama et al. [56]
found that AQP7 expression in the mesenteric fat is upregulated in
obese insulin resistant db+/db + mice, but downregulated by insulinsecreted in the feeding state. Subsequently, several studies in human
obesity demonstrated an increased AQP7 expression in visceral adipose
tissue [44,51,68] and a reduced [44,64,66,67] or an unmodiﬁed [51,69]
AQP7 expression in the subcutaneous adipose tissue. In normal weight
subjects, the visceral adipose tissue (usually a small mass compared to
the subcutaneous) can store more dietary fats and release more free
fatty acids under stimulation than the subcutaneous adipose tissue
[70,71,72,73]. Moreover, visceral fat is more strongly associated with
cardiometabolic risk factors than the subcutaneous fat depot [74].
As a whole, in obesity, the expression changes of AQP7 in the two
kinds of adipose tissue seem to cause both an increase in fat accumula-
tion in the subcutaneous depot and an increase in glycerol exit from the
visceral depot.
As for the possible correlation between AQP7 expression and type 2
diabetes, no conclusive results have emerged. Two studies reported an
increased AQP7 mRNA expression in visceral adipose tissue from type
2 diabetic patients [44,51] and one study reported a decreased AQP7
mRNA expression in the subcutaneous tissue [44]. Others observed no
differences in either the visceral [68,69] or the subcutaneous [51,53,
69] adipose tissue. Nevertheless, subjects with the -953G variant in
the AQP7 promoter have a reduced AQP7 expression and an increased
risk of obesity and/or type 2 diabetes [67]. As for other AQPs, differences
in their expression were observed in obesity-associated type 2 diabetic
patients: AQP3 expression was upregulated in both the visceral and the
subcutaneous adipose tissue, while AQP9 was upregulated only in the
visceral fat [44].
4. Liver
Multiple AQPs are expressed in the hepatobiliary system with the
following distribution: liver (AQP3, 7, 8, 9, 11), quiescent perisinusoidal
fat-storing cells (AQP 0, 1, 8 and 9), intrahepatic bile ducts (AQP1, 4),
gallbladder (AQP1, 4, 8) and endothelia and small vessels (AQP1) [15,
75,76]. In hepatocytes, AQPs show a speciﬁc localization: AQP8 in the api-
cal and subapical membranes and in organelles, AQP9 in the basolateral
sinusoidal surface membrane, AQP11 in the endoplasmic reticulum,
AQP3 and 7 not yet clariﬁed [2,15,75,76,77,78]. In the hepatobiliary
system the aquaglyceroporins are involved in various physiological
processes: 1) bile secretion, 2) detoxiﬁcation and 3) glycerol utilization
for gluconeogenesis by facilitating its entry into hepatocytes.
The process of bile secretion by hepatocytes and the subsequent
modiﬁcation in the bile duct by cholangiocytes requires a large amount
of water movement. Water is secreted by hepatocytes and then is
reabsorbed by cholangiocytes. Water basolaterally ﬂows from the sinu-
soidal blood into the hepatocytes through AQP9 and then is transferred
in the bile canaliculus through apical AQP8 (see scheme in [75]). Succes-
sively, under choleretic or cholestatic stimuli water can be secreted or
reabsorbed by apical AQP1 and basolateral AQP4, respectively (see
schematic representation in [75]). Water movement in the two direc-
tions is supported by endothelial AQP1.
The detoxiﬁcation function is achieved by the AQP9 expressed in he-
patocytes. Due to the wide permeability of the pore, AQP9 revealed an
unexpected permeability to arsenite (As(OH)3) [32,35] and to NH3
and NH4 [79] in addition to water and small polyols. It was suggested
that AQP9 transports arsenite (absorbed by the intestine or circulating)
and ammonia (originated in the intestine) from the blood into the
periportal hepatocytes, thus providing a route for their excretion and
thereby partially reducing their toxicity [32,34,35,79].
The liver is the organdesignated for glycerolmetabolism; the glycer-
ol released fromadipose tissue throughAQP7 enters the hepatocytes via
AQP9. Here, it is phosphorylated to glycerol-3-phosphate, a precursor
for both gluconeogenesis and TAG synthesis [4,44]. AQP9 is themain he-
patic aquaglyceroporin and the prevalent route of entry for glycerol into
the liver, both in the fed and in the fasting state [80]; any alteration in
AQP9 abundance determines a modiﬁcation in glycerol permeability
of the basolateral plasma membrane [81]. Other aquaglyceroporins,
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logical role has not been clariﬁed [44,78].
The physiological role of AQP9 in glycerol metabolism emerged in a
study in AQP9-KO mice [80]. After conﬁrming the high expression of
AQP9 in the liver with a plasmamembrane localization, the authors ob-
served an increase in both plasma glycerol and triglycerides, which is
consistent with an impaired glycerol metabolism. Finally, in Leprdb/db
mice, which developed obesity and type II diabetes after three to four
weeks, concurrent AQP9 depletion ameliorated their diabetic state: a
decreased hepatic uptake of glycerol decreases gluconeogenesis. Thus,
AQP9 seems to play a role not only in glycerol and glucose metabolism,
but also in the developing or worsening of diabetes mellitus.
The use of AQP9 as a possible therapeutic target has been suggested
even if a deeper comprehension of its role in hepatic triglyceride syn-
thesis is needed and these results still need to be conﬁrmed in humans.
It is noteworthy that the role of AQP9 in glycerol-glucose metabolism
and in detoxiﬁcation can be linked. During fasting or in diabetes, AQP9
mediates both the inﬂux of glycerol used for gluconeogenesis and the
efﬂux of urea from hepatocytes after ureagenesis [82,83].
The importance of AQP9 in glucose and glycerol metabolism and its
regulation by insulin has been previously investigated by Kuriyama and
coworkers [56]. These authors demonstrated a negative relationship be-
tween circulating insulin andhepatic AQP9 levels; in the liver of diabetic
mice AQP9 is over-expressed whereas in rat H4IIE hepatoma cells AQP9
levels are downregulated by insulin treatment. The effect of insulin is
due to the presence of a negative insulin response element (IRE) in
the promoter region of the AQP9 gene, which determines the suppres-
sion of AQP9 transcription. This regulation by insulin resembles that of
AQP7 in the fat tissue [50,63].
After a meal, insulin mediates the physiological reduction of lipoly-
sis, which results in reduced glycerol release (AQP7 downregulation)
and reduced glycerol uptake in the liver (AQP9 downregulation), there-
by slowing the gluconeogenesis process [50,56,63]. Further, obese and
insulin resistant db+/db+mice showed abnormally high levels of ad-
ipose AQP7 and liver AQP9 despite high insulin, and high glycerol and
high glucose plasma levels (in comparison to normal leanmice); this re-
sults in the stimulation of gluconeogenesis, which leads to a worsening
of hyperglycemia in the diabetic state [56].
The downregulation of hepatic AQP9 by insulin seems to occur only
in male rodents and to be prevented by estrogen in females [84].
The coordinated regulation of adipose and liver aquaglyceroporin
expression described above could play an important role both in the
normal physiological condition and in insulin-resistance. More recently,
Frühbeck's group reported a downregulation of AQP9mRNA in the liver
of Type 2 diabetic patients, a control mechanism that limits the uptake
of glycerol in the liver, to reduce gluconeogenesis and the further in-
crease of hyperglycemia in these patients [68].
The interesting roles of AQP9 in glycerol and glucose metabolism
both in normal conditions and in metabolic disorders, prompted the in-
vestigation of the regulation of AQP9 expression in the liver and possi-
bly the pathogenesis of some diseases. To this regard, the involvement
of p53 in enhancing gluconeogenesis has been studied by gene expres-
sion microarray in human liver-derived cells in different p53 statuses
[85]. Results showed a p53-dependent induction of the catalytic subunit
of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase 2,
but also the expression of glycerol kinase, glutamic-oxaloacetic trans-
aminase 1, and of AQP3 and AQP9 [85]. Therefore, p53 is demonstrated
to increase hepatic glucose production.
In human hepatoma HepG2 cells, AQP9 was downregulated by
AMP-activated protein kinase (AMPK) stimulation through the Akt-
FoxA2 pathway [86]. Notably, AMPK is an energy sensor in the homeo-
stasis of carbohydrate and lipid metabolism, also stimulated by metfor-
min, the oral antidiabetic drug belonging to the biguanide class.
Moreover, FoxA2 activity is inhibited by insulin, so in insulin-resistant
and Type-2 diabetic patients, this transcription factor is inactive, con-
ﬁned in the cytoplasm of hepatocytes [87]. As a consequence, FoxA2cannot reduce AQP9 expression, which in turn cannot reduce glycerol
uptake, thus promoting lipidmetabolismandketogenesis [87]. A similar
role has been attributed to the transcriptional factor peroxisome
proliferator-activated receptor alpha, which induces AQP9 expression
during starvation [88] to promote glucose metabolism, fatty acid oxida-
tion and ketogenesis [89].
Different results were obtained by Rodríguez et al., who found that
insulin upregulates AQP3, 7 and 9 and that leptin upregulates AQP3
and downregulates AQP7 and AQP9 in both human omental adipocytes
and HepG2 hepatocyte [44]. These different results were ascribed to
species differences.
Glycerol plays a fundamental role in maintaining the balance be-
tween lipid accumulation and hepatic gluconeogenesis, so variations
in AQP9 expression levels can weaken this delicate balance. For these
reasons the role of AQP9 in steatosis in non-alcoholic fatty liver disease
(NAFLD) and in steatohepatitis (NASH) has been examined [90,91,92].
In a NAFLD cell model transfected with an AQP9 recombinant plasmids,
AQP9 overexpression signiﬁcantly increased intracellular triglyceride,
free fatty acid and glycerol contents and worsened the steatosis, while
AQP9 suppression ameliorated the degree of steatosis. These results
suggest a novel molecular target for therapeutic intervention in
NAFLD [90].
In a different study conducted on human liver biopsies of obese and
insulin-resistant or diabetic patients, a downregulation of AQP9 emerged
in obese patients with type-2 diabetes, with NAFLD and NASH correlated
to the degree of steatosis. AQP9 was further reduced in insulin-resistant
individuals [92]. The reduced AQP9 expression and the subsequent
lower glycerol inﬂux into hepatocytes could be interpreted as a possible
compensatory response by the liver to prevent further triglyceride, free
fatty acid and glycerol accumulation and gluconeogenesis in NAFLD pa-
tients [92]. Conversely, other authors observed no correlation between
AQP9 liver expression and hepatic steatosis or ﬁbrosis in a group of mor-
bidly obese patients [69]. A possible molecular explanation of the altered
expression levels of AQP9 in hepatic steatosis is related to the presence of
oleic acid inside the cells. Treatment with this fatty acid downregulates
AQP3 and upregulates AQP9 in a concentration-dependent manner up
to 500 μmol/L [91]. In particular, oleic acid reduces AQP3 protein levels
by inducing the p38 MAPK pathway and increases AQP9 protein levels
by inactivating the PI3K/Akt pathway [91].
However, the physiological meaning for the supposed redundancy
of different aquaglyceroporins in human liver remains to be clariﬁed.
5. Small intestine
It is established that triglycerides in the intestinal lumen are hydro-
lyzed tomonoacylglycerols and free fatty acids. Pancreatic lipase further
hydrolyzes monoacylglycerols to free fatty acids and glycerol. It has
been previously demonstrated that about 75% of the glycerol present
in the dietary triglycerides is absorbed as monoglycerides and about
25% as free glycerol [93]. Also, glycerol is assumed in the free form as
food additive (E422) for its properties of sweetener, humectant, emulsi-
ﬁer, and as a support for other synthetic additives in several liqueurs,
syrups and baked goods. Glycerol in the free form is absorbed mainly
by the small intestine through AQPs, therefore contributing to the
total amount of circulating glycerol. In fact, the very low GK levels in
the small intestinal mucosa under basal, unstimulated conditions do
not allow glycerol to be utilized for triglyceride synthesis during the ab-
sorption of fats [94].
The ﬁrst glycerol gateway, AQP3, was identiﬁed thirty-ﬁve years ago
in the gastrointestinal tract of the rat [95]; more members of the AQP
family were later found. A total of AQP have been discovered in the
human small intestine (AQP1, 3, 7, 10 and 11),. Excluding AQP1
expressed in the capillary endothelium of the intestinal mucosa and
AQP11 whose transport properties have not been fully characterized,
all others are members of aquaglyceroporins family (for a review, see
[96]). In addition to the AQPs transport route, a carrier-mediated
6 U. Laforenza et al. / Biochimica et Biophysica Acta 1858 (2016) 1–11glycerol transport has been identiﬁed and characterized in the rat small
intestine [97].
Successively, AQP10 has been shown to have carrier features, being
saturable and inhibited by structural analogs of glycerol [98], in addition
to its previously known properties of a glycerol facilitator channel. The
dual functional characteristic of AQP10 as a channel/carrier seems to
be shared by hAQP9, another human aquaglyceroporin highly
expressed in the liver: [99]; however, this is still controversial and
needs to be conﬁrmed.
Although there are still uncertainties about the exact localization of
AQPs, their function as water channels in both normal and pathologic
conditions, like infectious diarrhea, inﬂammatory bowel disease and ce-
liac disease, has been documented [96,100,101,102]. Up- or down-
regulation of AQPs is strictly related to altered gastrointestinalwater ab-
sorption or secretion, but what about its involvement in glycerol
homeostasis?
The ﬁrst clue to the importance of aquaporins in the metabolism of
glycerol appeared in a study in AQP3 null mice [103]. Analysis of
serum parameters did not show any difference between AQP3 null
and wild-type mice, except for triglyceride levels that were halved in
the AQP3 null mice: the authors correlate the hypotriglyceridemia in
AQP3 deﬁcient mice with the glycerol transporting property of AQP3.
The second clue more directly indicates that, in Caco-2 cells, AQP3
gene expression, and thus glycerol intestinal absorption, is controlled
by hormones and drugs (like insulin, the antidiabetic drugs troglitazone
and tolbutamide and epinephrine) that regulate blood glucose [104].
Thismight suggest that the free glycerol absorbed by the small intestine
could be implicated in glycemic homeostasis, although it is not clear
how much glucose originates from the pool of glycerol absorbed.
6. Kidney
Animal studies have previously demonstrated that, at normal con-
centration, glycerol is almost completely reabsorbed in the proximal
part of the nephron by a “conversion or reabsorption” mechanism
[105]. Normal serum glycerol concentration in adults is about
0.065–0.1mmol/L, and rarely exceeds 0.33–0.43mmol/L under lipolytic
conditions [1,106,107,108,109]. Glycerol is usually completely
reabsorbed by kidney under physiological conditions and begins to ap-
pear in the urine when plasma glycerol concentrations exceed its satu-
ration point [105]. In dogs and in cats, the saturation point for glycerol is
signiﬁcantly higher than in humans: 1.1–1.62 mmol/L [109,110]. How-
ever, a large amount of the glycerol that enters the kidney proximal tu-
bule cells is used in the gluconeogenesis process, which contributes up
to 20–25% of the whole-body glucose production [111,112].
There is no need to emphasize the importance of aquaporins in the
urinary concentration function: the osmotic water transport across the
tubule epithelium is an AQP-facilitated mechanism (for reviews, see
[15,113,114]). So far, eight AQPs have been identiﬁed in the mammal
kidney: AQP1, 2, 3, 4, 6, 7, 8, 11, each characterized by a speciﬁc cellular
or subcellular localization [15].
As for aquaglyceroporins, AQP3 is abundantly expressed in the
basolateral plasma membranes of the collecting duct principal cells,
while AQP7 is expressed in the brush border plasma membranes of
the proximal tubule cells of the S3 segment [15].
Transgenic mice studies have provided fundamental insight into
AQPs functions in renal physiology.
Experiments with AQP3-KO mice demonstrate the involvement of
AQP3 in the urinary concentration function, where AQP4 represents
the exit pathway in transcellular water transport [103,114].
Experiments with AQP7 null mice demonstrated a small but signiﬁ-
cant reduction inwater permeability of the proximal tubule brush border
membranes concomitant with a drastic increase of urinary glycerol con-
centration, with a 340-fold increase in glycerol concentration in the KO
vs.WT. Similar increases in urinary glycerol concentrationwere observed
in another AQP7-KO mouse model [52]. However, it is not clear if renalglycerol excretion in AQP7-KO mice can affect serum glycerol concentra-
tion: while Maeda et al. show a signiﬁcantly lower plasma glycerol in
AQP7 null mice compared to controls, both in the fed and fasted state
(about 53% and 38%, respectively) [55], other authors showed either a
small, non signiﬁcant reduction (about 15%decrease) [115] or no changes
[52]. In humans, three unrelated homozygous G264V mutant children
had normal plasma glycerol levels but a very high concentrations of glyc-
erol in the urine, ranging from 500 to 2800mmol glycerol/mol creatinine
in themutant subjects vs. b 1mmol glycerol/mol creatinine in the normal
subjects [65].
The studies above indicate that AQP7 functions as an entryway into
the cells of the S3 segment, which is mainly involved in the reabsorption
of glycerol. The same studies suggest that the deletion of AQP7 cannot be
compensated by either AQP3 or other still unknown aquaglyceroporins.
7. Microvessels
A possible role of capillary aquaglyceroporins in the tissue handling
of glycerol emerged from the study of Skowronski et al. [52]. The au-
thors showed that AQP7 is localized in the endothelium of both brown
and white adipose tissue capillaries, the heart, and skeletal muscles,
but is surprisingly absent from the plasma membranes of either adipo-
cytes or myocytes. Further, AQP7 expression in microvessels is doubled
in streptozotocin-induced diabetes mellitus and in prolonged fasting
[52]. For the ﬁrst time, it has been proposed that insulin regulates the
functioning of adipose tissue by controlling glycerol entry/exit through
the vascular endothelium [52]. In humans, colocalization experiments
of AQP7 and AQP10 with CD34, an endothelial cell marker, conﬁrmed
AQP7 expression in the endothelium of adipose tissue capillaries, and
also demonstrated the presence of AQP7 in the plasma membranes of
adipocytes; AQP10 was found to be localized in the adipocytes and
not in the capillaries [45]. In the human small intestine, an AQP10 vari-
ant was found in the endothelial cells of the villus capillaries by Li et al.
[116].
We are tempted to speculate that also in the small intestine
aquaglyceroporin expression may be regulated by the hormones and
drugs that regulate glycerol absorption.
Unfortunately, no evidence has yet been found of aquaglyceroporin
expression in kidney capillaries, but their existence (and physiological
importance) cannot be excluded.
8. Endocrine pancreas
Insulin secretion is physiologically turned on after a meal by the in-
creased plasma concentration of glucose, free fatty acids and amino
acids [117,118]. Glycerol does not seem to have a role in eliciting insulin
secretion due to the low intracellular concentration of GK [119,120].
However, the artiﬁcial induction of GK in pancreaticβ-cell experimental
modelsmakes the cells responsive to glycerol, whichGK converts to lac-
tate and glucose, for insulin production and secretion [119,120]. The
possible role of glycerol content in the regulation of insulin secretion
aswell as in the aquaglyceroporins expressionwas successively investi-
gated in pancreatic β-cells [62]. Of the four known mammalian aqua-
glyceroporins, only AQP7 was expressed in the β-cells of mouse
pancreas. The role of AQP7 was further investigated by generating an
AQP7-null mouse model. Compared to normal mice, Aqp7−/− mice
showed: 4–5-fold higher plasma insulin concentration without signs
of insulin resistance, increased glycerol concentration in pancreatic is-
lets, increased GK expression and activity, and increased triglyceride
levels, reduced β-cell mass, higher abundance of intracellular insulin
transcripts and lower intracellular insulin [62]. The authors concluded
that AQP7 could be involved in insulin synthesis and secretion as well
as in controlling β-cell mass.
Recently, a novel mechanism of insulin secretion has been proposed
in addition to that of themetabolically-regulated ATP-sensitive K+ chan-
nels. A rise in plasma glucose concentration determines its increased
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rectly (through its metabolites). The swelling activates chloride efﬂux
mediated by the volume-regulated anion channels (VRAC), membrane
depolarization, the opening of voltage sensitive Ca2+ channels, and
Ca2+ entry, which in turn promotes insulin secretion [118,121,122,
123]. In this scenario, the role [of aquaglyceroporins in insulin secretion,
and in particular of AQP7, has been investigated. Results obtained using
pancreatic islets showed that the addition of isotonic and hypertonic
glycerol caused β-cell swelling possibly through AQP7, VRAC activation,
membrane depolarization and insulin release [123]. These data were
also suggestive of an additional role of glycerol in insulin secretion relatedFig. 1. Possible model of aquaglyceroporins involvement in the homeostatic regulation of plasm
withmechanisms involving aquaporin-7 and -10 (AQP7 and 10) at the apical side and aquaporin
the capillaries through an aquaporin-10 variant (AQP10v). In the adipocytes, glycerolmovemen
by AQP3, 7 and 10, while the entry of glycerol occurs through AQP9. AQP11 is involved in the tra
is transported into or out of the microvessels through AQP7. In the kidney, glycerol is partially r
tubule cells of S3 segment. The mechanism by which glycerol passes across the basolateral sid
mainly from lipolysis, from intestinal absorption, and in part also from kidney reabsorption) e
to be used for gluconeogenesis. Glycerol as such can also be used also as an energy substrate by
aquaglyceroporin expression can be regulated by insulin, whose secretion is probably under th
creatic β-cells through AQP7.to glycerol metabolism, even though the GK expression in pancreatic β-
cells is uncertain and the glycerol concentrations used were not in the
physiological range [123]. The role of AQP7 and of glycerol in β-cell func-
tion was further conﬁrmed by using pancreatic islets from AQP7−/−
mice [118,121]. Results showed a signiﬁcantly lower release of insulin
in AQP7−/− mice after the iso-osmotic addition of glycerol or D-
glucose, or in response to extracellular hypotonicity in comparison to
wild-type mice [118,121].
These results appear to be consistent with a positive relation be-
tween AQP7 expression and insulin secretion, but are at evident conﬂict
with previous ones, which reported a negative relation [62]. Futurea glycerol concentration. Glycerol absorption by the small intestinal epithelial cells occurs
-3 (AQP3) at the basolateral side. Glycerol accumulation in the interstitium is drained into
t into or out of the lipid droplets aswell as the exit from the plasmamembrane ismediated
nsport of glycerol into/out of the lipid droplets. Depending on themetabolic state, glycerol
eabsorbed via the AQP7 localized in the brush border plasma membranes of the proximal
e and into the capillary endothelial cells is still unknown. Circulating glycerol (originating
nters hepatocytes through aquaporin-9 (AQP9), at the basolateral sinusoidal membrane,
the heart or skeletal muscle, entering through plasma membrane AQP3 and AQP7. Tissue
e control (negative or positive is yet to be deﬁned) of glycerol itself, that enters into pan-
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insulin release.
9. Heart and skeletal muscle
The cardiac tissue of different mammalian models (humans, mice
and rats) has been analyzed for AQPs and their possible dual functional
role: 1) water handling in both normal and pathological (myocardial
edema) conditions, and 2) the uptake of glycerol, a substrate for energy
production, into cardiomyocytes. Almost all AQP transcripts, AQP1, 3, 4,
5, 7, 8, 9, 10 and 11, were found in the heart of mammals, but only the
AQP1, 3, 4, and 7 were conﬁrmed at protein level [52,124,125,126,
127]. While in normal conditions AQP1 and 4 are mainly involved in
myocardial water balance, in edema and in ischemia reperfusion injury
[124], AQP3 and especially AQP7 may play a role in cardiac energy pro-
duction [124].].
Small amounts of AQP9 transcript were detected in both rat and
human heart [43,125], but the protein was absent [35,126]. Interesting-
ly, the increased expression of the AQP9 gene in infective endocarditis
patients who experienced acute heart failure, suggests AQP9 is a poten-
tial prognostic factor for infective endocarditis [128]. The expression of
the AQP3 protein in the heart is still uncertain: previously found in car-
diac muscle by using human tissue microarrays [127], its presence in
cardiac tissue was successively excluded [125,126].
At present, AQP7 is the only recognized glycerol channel expressed
in the heart, localized in myocytes, ﬁbroblasts and in capillaries [52,63,
125,126,129]. Relevant insights were obtained with studies in AQP7-
KO mice. Skowronski and coworkers revealed a speciﬁc signal in the
capillaries but not in cardiomyocytes [52]. This localization in the capil-
laries is similar to what observed in the adipose tissue. Successively, the
roles of cardiac AQP7 and of glycerol as an energy substrate of the heart
were evidenced using a different AQP7-KO mouse model [126]. After
conﬁrming that AQP7 is the sole aquaglyceroporin in the mouse heart,
Hibuse et al. [126] demonstrated that AQP7 silenced cardiomyocytes
and cardiac tissue of AQP7-KO mice have lower glycerol and ATP con-
tents than WT, consistent with a reduced glycerol entry into the cells.
Further, cardiac overload by transverse aortic constriction and by con-
tinuous isoproterenol infusion for 1–2weeks resulted in severe left ven-
tricular hypertrophy in AQP7-KOmice and in a lower survival rate than
in wild-typemice. Taken together, the results demonstrate that AQP7 is
involved in the transport of glycerol in the cardiac muscle and that the
glycerol taken up can be considered one of the energy sources of the
heart, as it is converted to pyruvate by GK and glycerol-3-phosphate de-
hydrogenase−2.
Fewdata are available on the expression and function of aquaglycero-
porins in the skeletal muscle of mammals. AQP3 transcript was ﬁrst
found by RNase protection assay in the skeletal muscle of rat [130] and
was successively conﬁrmed also at protein level in humans [127,131]. Im-
munoﬂuorescence and immunohistochemistry showed that the protein
is localized in the sarcolemma of slow-twitch human type 1 muscle ﬁ-
bers, and immunoelectron microscopy suggests its possible costameric
distribution [131]. The localization in intramembranous particleswas fur-
ther conﬁrmed by a fracture-label study, suggesting a role of AQP3 (to-
gether with AQP4) in maintaining osmotic homeostasis in the skeletal
myoﬁbers [132].
A second aquaglyceroporin was found at both mRNA and protein
levels in the human and mouse skeletal muscle: the AQP7. The AQP7
protein was localized in themyoﬁber surface of type 1 and type 2 ﬁbers
in human muscles and of type 2 ﬁbers in mouse muscles, but its func-
tional role has not yet been analyzed [133]. Different results surprisingly
showed a speciﬁc signal in the capillaries but not in the sarcolemma of
skeletalmuscle ﬁbers [52], similarly towhat found for the adipose tissue
and the heart.
Finally, as regards AQP9, only aweak expression of itsmRNAwas ob-
served in the skeletal muscle of mice [134] but, to date, no new results
have emerged about the protein and its possible functional role.As a whole, the aquaglyceroporins appear to be involved in supply-
ing glycerol to the cardiac and skeletal muscle for energy production.
This metabolic function of aquaglyceroporins is supported by the fact
that insulin treatment decreases both AQP7 expression in the adipose
tissue and triglyceride content in muscle tissue of mice [135].
Even thoughwith some limitations (i.e. the extrapolation to humans
of data obtained in rodents), the results are promising and beg further
investigation.
10. Concluding remarks
As a whole, the involvement of AQPs in glycerol metabolism has
been well documented. AQPs represent pathways for glycerol absorp-
tion by the gastrointestinal tract, for partial glycerol reabsorption or se-
cretion by the kidney and for entry/exit processes in adipocytes,
depending on the metabolic state of the organism. The glycerol thus
made available can be used also as fuel by the heart and skeletal muscle
and as a substrate for gluconeogenesis by the liver. Aquaglyceroporins
in the capillaries may function as channels that modulate glycerol
ﬂow into and out of the bloodstream. A hypothetical working model
for the involvement of aquaglyceroporins in the homeostatic regulation
of plasma glycerol is summarized in Fig. 1.
Since AQPs can be controlled by hormones and drugs, theymay rep-
resent potential therapeutic targets in the management of obesity and
associated metabolic disorders. Thiazolidinediones, insulin sensitizer
drugs for the treatment of type-2 diabetes and agonists of peroxisome
proliferator-activated receptor γ, have revealed an upregulating effect
on AQP7 in murine 3 T3-L1 cells and in OLETF rats [57,136]. Recently,
Apelin-13was demonstrated to reduce the lipid accumulation in hyper-
trophic adipocytes in vitro by increasing AQP7 expression, which indi-
cates it could be used as an AQP modulator in the treatment of obesity
[137]. A novel small molecule inhibitor of AQP9, HTS13286, has been
identiﬁed and recognized to be effective in reducing glycerol gluconeo-
genesis in primary hepatocyte cultures [138]. However, at present, its
therapeutic use cannot be recommended due to the high doses required
and the low solubility in 1% DMSO aqueous solution.
We are only beginning to understand the importance and scope of the
subject of AQPs, their function, and their promise as potential therapeutic
targets, a promising ﬁeld that that deserves further investigation.
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